Role of TGFB1 as a biomarker in early HCC

Document Type : Original Article

Authors

Department Internal medicine, Minia University, Egypt

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause 
of cancer-related death worldwide. Aim of the study to assess the value of transforming beta binding 
protein-1 in plasma as a biomarker for early detection of hepatocellular carcinoma in chronic hepatitis 
C infection. Patients and methods: This cross-sectional prospective, case-control hospital based 
study was conducted in Internal Medicine Department, Minia University Hospital in collaboration of 
our Radiology department and South Egypt Cancer Institute from June 2018 to June 2019. In this 
study included 90 subjects who were recruited from in patient and out -patient clinic and divided into 
three groups. Results: Simple logistic regression analysis of AFP and TGF-B1 for prediction of HCC 
among cirrhotic patients revealed that; increase TGF-B1by one unit will increase the risk of HCC by 
3.7% (OR=1.037, 95%CI= 1.01-1.05, P value = 0.002), while; increase AFP by one unit will increase 
the risk of HCC by 2.7% (OR=1.027, 95%CI= 1.02-1.06, P value <0.001). Conclusion: We evaluated 
the serum levels of TGF-β1 in HCC patients, cirrhotic patient and normal subjects. Its aim was to 
determine the early prediction of hepatocellular carcinoma associated chronic hepatitis c virus.

Keywords

Main Subjects

Files

Share

How to cite

Statistics